5,184,716 Shares in Stryker Corporation $SYK Purchased by Norges Bank

Posted by George Bondi on May 30th, 2026

Norges Bank bought a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm bought 5,184,716 shares of the medical technology company’s stock, valued at approximately $1,822,272,000.

Other large investors have also recently added to or reduced their stakes in the company. Czech National Bank raised its holdings in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the period. Davis R M Inc. raised its holdings in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares during the period. Terra Alpha Investments LLC purchased a new position in shares of Stryker in the 3rd quarter worth about $1,216,000. Kepler Cheuvreux Suisse SA purchased a new position in shares of Stryker in the 3rd quarter worth about $27,952,000. Finally, Daymark Wealth Partners LLC raised its holdings in shares of Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after purchasing an additional 37,307 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of NYSE:SYK opened at $305.73 on Friday. The company has a market cap of $117.21 billion, a P/E ratio of 35.39, a PEG ratio of 1.94 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The business’s 50-day simple moving average is $321.82 and its 200 day simple moving average is $348.15.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research reports. Needham & Company LLC cut their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Wells Fargo & Company cut their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Finally, JPMorgan Chase & Co. cut their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $395.48.

View Our Latest Stock Analysis on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.